(paliperidone palmitate)
This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 07/12/2024
Data is available for situations outside of recommended storage requirements. This information is provided in response to your unsolicited request. These data were collected in strictly controlled environments. It is not possible to predict and design studies that reflect every combination or duration of temperatures that a customer’s product may encounter. Therefore, caution is recommended in assessing the effects of specific excursions on a product.
Stability studies were conducted with INVEGA SUSTENNA to provide the acceptable limits for temperature excursions outside of the recommended storage condition. Based on the stability data, INVEGA SUSTENNA was not adversely affected when exposed to conditions within the acceptable limits.
Acceptable Limit | |
---|---|
5°C (41°F) up to and including 15°C (59°F) | 3 months |
-10°C (14°F) up to and including 5°C (41°F) | 7 days |
1 | INVEGA SUSTENNA (paliperidone palmitate) extended-release injectable suspension [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/INVEGA+SUSTENNA-pi.pdf. |
2 |